02
Dec
By Eric Schweibenz
On November 29, 2013, the U.S. International Trade Commission issued a press release announcing their vote to institute an investigation of Certain Antivenom Compositions and Products Containing the Same (Inv. No. 337-TA-903).

The investigation is based on an October 20, 2013 complaint and a November 19, 2013 letter supplementing the complaint filed by BTG International Inc., of West Conshohocken, Pennsylvania alleging violations of Section 337 in the importation into the U.S. and sale of certain antivenom compositions and products containing the same that infringe one or more claims of U.S. Patent No. 8,048,414.  See our November 1, 2013 post for more details on the complaint.

According to the Notice of Investigation, the Commission has identified Veteria Laboratories of Mexico; BioVeteria Life Sciences of Prescott, Arizona; Instituto Bioclon S.A. de C.V. of Mexico; Laboratories Silanes SA de CV of Mexico; The Silanes Group of Mexico; and Rare Disease Therapeutics, Inc. of Franklin, Tennessee as the respondents in this investigation.

Lastly, Chief ALJ Charles E. Bullock issued a notice indicating that he will be the presiding Administrative Law Judge in this investigation.